Health Care

Edwards Lifesciences raised its full-year earnings forecast, anticipating stronger sales of its artificial heart valves.

Dow component Pfizer reported an adjusted 4Q profit of $0.53 per share, topping the estimate for $0.52. Revenue for the drugmaker came in at $14 billion, also beating the estimate for $13.56 billion.

Drugmaker Abbott Laboratories said it would acquire Alere for $5.8 billion to boost its global diagnostics presence.

Health insurer Aetna reported a 38 percent rise in quarterly profit, helped by strong performance in its government business that sells Medicare and Medicaid plans.

Generic drug maker Actavis agreed to acquire Warner Chilcott in an all-stock deal that values the Irish company at roughly $5 billion.

Campbell Soup revealed stronger-than-expected third-quarter earnings and boasted a full-year outlook above analyst forecasts on Monday.

The $100 billion of stimulus money that boosted funding for Medicaid will run out at the end of June, leaving states in a tough spot.

Richard Scrushy said he is looking forward to having the rest of his corruption charges thrown out by the Supreme Court.

Eli Lilly reported an adjusted 4Q profit of $0.78 per share, matching the estimate. Revenue for the drugmaker came in at $5.38 billion, beating the estimate for $5.3 billion.

Health insurer Anthem reported a net profit that fell short of analysts' estimates, hampered by weakness in its Obamacare business.

Health insurer WellPoint could have its pick of several industry executives to replace CEO Angela Braly who's exit from the company was announced late Tuesday night. 

Boston Scientific is reportedly planning on reversing at least some of the restructuring put in place by its former CEO by separating the two main divisions of its biggest business and is preparing another round of job cuts.

Medtronic was granted approval for a new device used to treat paroxysmal atrial fibrillation.